Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;61(12):1350-1356.
doi: 10.1097/DCR.0000000000001219.

What Is the Risk of Anal Carcinoma in Patients With Anal Intraepithelial Neoplasia III?

Grace C Lee  1 , Hiroko Kunitake, Holly Milch, Lieba R Savitt, Caitlin E Stafford, Liliana G Bordeianou, Todd D Francone, Rocco Ricciardi
Affiliations

What Is the Risk of Anal Carcinoma in Patients With Anal Intraepithelial Neoplasia III?

Grace C Lee et al. Dis Colon Rectum. 2018 Dec.

Abstract

Background: The risk of anal carcinoma after previous diagnosis of anal intraepithelial neoplasia III is unclear.

Objective: The purpose of this study was to estimate the risk of anal carcinoma in patients with anal intraepithelial neoplasia III and to identify predictors for subsequent malignancy.

Design: This was a retrospective review using the Surveillance, Epidemiology, and End Results registry (1973-2014).

Setting: The study was composed of population-based cancer registries from the United States.

Patients: Patients who were diagnosed with anal intraepithelial neoplasia III were included.

Main outcome measures: The primary outcome was rate of subsequent anal squamous cell carcinoma. Predictors for anal cancer were identified using logistic regression and Cox proportional hazard models.

Results: A total of 2074 patients with anal intraepithelial neoplasia III were identified and followed for a median time of 4.0 years (interquartile range, 1.8-6.7 y). Of the cohort, 171 patients (8.2%) subsequently developed anal cancer. Median time from anal intraepithelial neoplasia III diagnosis to anal cancer diagnosis was 2.7 years (interquartile range, 1.1-4.5 y). Fifty-two patients (30.4%) who developed anal carcinoma were staged T2 or higher. Ablative therapies for initial anal intraepithelial neoplasia III were associated with a reduction in the risk of anal cancer (OR = 0.3 (95% CI, 0.1-0.7); p = 0.004). Time-to-event analysis revealed that the 5-year incidence of anal carcinoma after anal intraepithelial neoplasia III was 9.5% or ≈1.9% per year.

Limitations: The registry did not record HIV status, surveillance schedule, use of high-resolution anoscopy, or provider specialty.

Conclusions: In the largest published cohort of patients with anal intraepithelial neoplasia III, ≈10% of patients were projected to develop anal cancer within 5 years. Nearly one third of anal cancers were diagnosed at stage T2 or higher despite a previous diagnosis of anal intraepithelial neoplasia III. Ablative procedures were associated with a decreased risk of cancer. This study highlights the considerable rate of malignancy in patients with anal intraepithelial neoplasia III and the need for effective therapies and surveillance. See Video Abstract at http://links.lww.com/DCR/A764.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest.

Figures

Figure 1.
Figure 1.
Kaplan-Meier curves depicting anal squamous cell carcinoma-free survival in patients with previous AIN III in (a) the overall cohort, and (b) separated by type of surgical intervention for prior AIN III.
See this image and copyright information in PMC

Comment in

References

    1. Ricciardi R Anal Intraepithelial Neoplasia. In: Steele SR, Hull TL, Read TE, Saclarides TJ, Senagore AJ, Whitlow CB, editors. The ASCRS Textbook of Colon and Rectal Surgery 1. 3 ed. Arlington Heights, IL.: Springer; 2016. p. 343–353.
    1. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:320–326. - PubMed
    1. Saleem AM, Paulus JK, Shapter AP, Baxter NN, Roberts PL, Ricciardi R. Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol 2011;117:643–649. - PubMed
    1. Society AC. Cancer Facts & Figures 2017. Special Section: Rare Cancers in Adults Atlanta: American Cancer Society; 2017.
    1. Simard EP, Watson M, Saraiya M, Clarke CA, Palefsky JM, Jemal A. Trends in the occurrence of high-grade anal intraepithelial neoplasia in San Francisco: 2000–2009. Cancer 2013;119:3539–3545. - PMC - PubMed

Publication types

MeSH terms